


Enhancing Delivery Of Biopharmaceutics Classification System Class II Drugs Through a Novel Alginate/Carrageenan/Oleogel Matrix: A Case Study On Praziquantel for Improved Therapeutic Efficacy


Nsanzubuhoro, C. N. & Tai, S. L.

## Introduction

Schistosomiasis is a waterborne and neglected tropical disease prevalent in Sub-Saharan Africa and South-East Asia. Limitations of the oral administration of the biopharmaceutics classification system (BCS) class II drug, praziquantel (PZQ), include its bitter taste, limited efficacy against juvenile worms, and low bioavailability due to its lipophilicity. In an effort to enhance the efficacy of PZQ, a novel drug delivery system composed of alginate, AG, carrageenan, CG, and a wax-based oleogel will be developed. The study will employ analytical methods including differential scanning calorimetry (DSC) for thermal behaviour analysis, confocal light microscopy for material morphology observations, fouriertransform infrared spectroscopy (FTIR) for understanding release mechanisms, high-performance liquid chromatography (HPLC) for quantifying release material concentration, and the Instron instrument for determining the Young modulus. Additionally, release kinetics will be investigated through dissolution studies using the United States Pharmacopeia (USP) 1 basket method.



## Alginate/Carrageenan/Oleogel



- Ion

Figure 2: Schematic of the pH-responsive behaviour of drug-loaded alginate (adapted from Agüero et al., 2017, a); The potential gelling mechanism of (, K-CG (adapted from Cunha and Grenha, 2016, b); composition of wax-based oleogel used In the study (c)

## **Aims and Objectives**

Aim: To develop a ternary drug delivery system using natural polymers (alginate and carrageenan) and oleogel to enhance drug absorption by improving bioavailability through sustained release of PZQ, and ultimately enhance drug efficacy for the treatment of schistosomiasis. Objectives:

- To investigate the structural, physical and dissolution behaviour of the i) AG/CG hybrid gel (without oleogel) by varying AG:CG ratios; ii) pure oleogel with varying oil and gelling agents of different melting points; iii) AG:CG:oleogel gel bead by varying the AG:CG to oleogel ratios. • To study the time release of AG, CG and oleogel of the AG/CG/oleogel gel bead under simulated stomach and intestinal gastrointestinal environments.
- To investigate and to apply design of experiments (e.g. surface response methodology or factorial design) in understanding the release behaviour of praziguantel within the AG/CG/oleogel bead in comparison to free PZQ.

## **Study Justification**

AG/CG/PZQ-loaded oleogel - little to none dissolved by saliva	Stomach pH 1.0 – 3.0	AG/CG break down at neutral and alkaline conditions. Bile salts, lipase enzymes present will break down the oleogel. Drug is released (primary site of absorption).	of absorption for enhanced bioavailability
• Mouth pH 6.8 – 7.5	•	Small intestines (duodenum, jejunum and lleum) pH 5.0 – 7.0	pH 7.5 – 8.0
Presence of form a gel.	AG/CG protects the drug from	dissolving in acidic environment-	Further drug absorption




Figure 4: Schematic of methodology (created with Chemix 2023)

forward together  $\cdot$  sonke siya phambili  $\cdot$  saam vorentoe